These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 33500730)

  • 1. Endocytic pathway inhibition attenuates extracellular vesicle-induced reduction of chemosensitivity to bortezomib in multiple myeloma cells.
    Tu C; Du Z; Zhang H; Feng Y; Qi Y; Zheng Y; Liu J; Wang J
    Theranostics; 2021; 11(5):2364-2380. PubMed ID: 33500730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxic Bone Marrow Stromal Cells Secrete miR-140-5p and miR-28-3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma.
    Zhang H; Du Z; Tu C; Zhou X; Menu E; Wang J
    Cancer Res; 2024 Jan; 84(1):39-55. PubMed ID: 37756570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.
    Wang J; Hendrix A; Hernot S; Lemaire M; De Bruyne E; Van Valckenborgh E; Lahoutte T; De Wever O; Vanderkerken K; Menu E
    Blood; 2014 Jul; 124(4):555-66. PubMed ID: 24928860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of multiple myeloma‑derived exosomes uptake suppresses the functional response in bone marrow stromal cell.
    Zheng Y; Tu C; Zhang J; Wang J
    Int J Oncol; 2019 Mar; 54(3):1061-1070. PubMed ID: 30664188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis.
    Costa Verdera H; Gitz-Francois JJ; Schiffelers RM; Vader P
    J Control Release; 2017 Nov; 266():100-108. PubMed ID: 28919558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
    Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
    Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Marrow Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Promote Periodontal Regeneration.
    Liu L; Guo S; Shi W; Liu Q; Huo F; Wu Y; Tian W
    Tissue Eng Part A; 2021 Jul; 27(13-14):962-976. PubMed ID: 32962564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
    Jones RJ; Singh RK; Shirazi F; Wan J; Wang H; Wang X; Ha MJ; Baljevic M; Kuiatse I; Davis RE; Orlowski RZ
    Front Immunol; 2020; 11():1816. PubMed ID: 32903557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
    Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
    Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
    Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
    J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
    Longo J; Smirnov P; Li Z; Branchard E; van Leeuwen JE; Licht JD; Haibe-Kains B; Andrews DW; Keats JJ; Pugh TJ; Trudel S; Penn LZ
    Leukemia; 2021 Mar; 35(3):796-808. PubMed ID: 32665698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
    Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
    J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
    Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
    Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
    Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
    Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis.
    Zarfati M; Avivi I; Brenner B; Katz T; Aharon A
    Angiogenesis; 2019 Feb; 22(1):185-196. PubMed ID: 30386953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMSC-Derived Small Extracellular Vesicles Induce Cartilage Reconstruction of Temporomandibular Joint Osteoarthritis
    Wang Y; Zhao M; Li W; Yang Y; Zhang Z; Ma R; Wu M
    Front Cell Dev Biol; 2021; 9():656153. PubMed ID: 33869221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.